DT2216 – Patient Worthy

Photo by National Cancer Institute on Unsplash

DT2216 Earns Fast Track Designation for PTCL, CTCL

Post author:Jessica Lynn
Post published:April 15, 2022
Post category:Cutaneous T-cell Lymphomas Peripheral T-cell lymphoma

On April 6, 2022, biotechnology company Dialectic Therapeutics announced via press release that its therapeutic candidate DT2216, designed for relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) or peripheral T-cell…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More